{"product_id":"ibio-vrio-analysis","title":"iBio, Inc. (IBIO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs iBio, Inc. (IBIO) truly built for lasting success? This VRIO analysis rigorously tests the core of their business - its Value, Rarity, Inimitability, and Organization - to uncover whether they possess a sustainable competitive advantage. Dive in now to see the definitive verdict on what truly sets iBio, Inc. (IBIO) apart from the competition and where their future strength lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: AI-Driven Antibody Discovery Platform (Machine-Learning Antibody Engine)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the engine room of iBio, Inc. (IBIO), their AI-Driven Antibody Discovery Platform. This isn't just software; it’s the core mechanism driving their pivot into precision therapeutics, especially in the hot obesity and cardiometabolic space. We need to assess if this technology is truly creating a competitive moat based on the 2025 results.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Accelerating Development for Next-Gen Obesity Treatments\u003c\/h3\u003e\n\u003cp\u003eThe platform’s value proposition centers on speed and quality. It accelerates lead identification and optimization, engineering antibodies for high developability and extended half-life, which is key for next-gen obesity treatments like IBIO-600. For instance, the platform helped advance IBIO-600, the long-acting anti-myostatin antibody, into IND-enabling studies during fiscal year 2025. Also, the resulting Activin E antibody, IBIO-610, showed compelling preclinical data, achieving 26% fat mass reduction while preserving lean mass. This efficiency is critical; the platform can shorten antibody optimization timelines to under four weeks versus the traditional 4-8 months.\u003c\/p\u003e\n\u003cp\u003eThe platform’s direct output in FY2025 included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdvancing IBIO-600 into IND-enabling studies.\u003c\/li\u003e\n\u003cli\u003eAdvancing IBIO-610 to development candidate selection.\u003c\/li\u003e\n\u003cli\u003eIdentifying all four targets plus a fifth under the AstralBio collaboration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: A Unique, Integrated Technology Stack\u003c\/h3\u003e\n\u003cp\u003eThe combination of proprietary tools within a single integrated stack is quite rare in the preclinical space. This isn't just one AI model; it’s a suite of specialized components working together. The rarity comes from the specific integration of these patented technologies:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEpitope steering technology.\u003c\/li\u003e\n\u003cli\u003eStableHu™ Antibody Optimizer.\u003c\/li\u003e\n\u003cli\u003eEngageTx™ for engineering bispecifics.\u003c\/li\u003e\n\u003cli\u003eShieldTx® for antibody masking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis stack allows them to target subdominant epitopes, which traditional methods often miss, increasing the chance of finding truly efficacious candidates.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier Due to Proprietary Data and Tuning\u003c\/h3\u003e\n\u003cp\u003eHonestly, while the underlying AI\/ML concepts are known across the industry, the specific, proprietary datasets and the fine-tuned algorithms developed over time are difficult and time-consuming to replicate. Imitability is high because the value is locked in the iterative learning process. It took years of work to build the data sets that inform the current models. For example, the platform’s success in engineering IBIO-600 for an extended half-life and IBIO-610 for fat-selective loss represents accumulated, non-transferable knowledge embedded in the system. Replicating this would require matching both the technology and the unique, hard-won data history.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Strong Alignment to Pipeline Execution\u003c\/h3\u003e\n\u003cp\u003eThe organization is strong because the platform directly enabled the rapid advancement of key pipeline assets and the in-licensing of IBIO-600 and IBIO-610 from AstralBio, securing full development rights. The company’s financial structure in FY2025 reflects this focus: R\u0026amp;D expenses increased 59.6% year-over-year to $8.3 million to support these assets. They also successfully accessed capital markets, raising $50 million (or $46.5 million in one reported offering) to fund this development, showing management is organized to support the platform’s output. They’ve created an organizational model where all disciplines have expertise in artificial intelligence, breaking down conventional barriers between data scientists and biologists.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the resource allocation supporting the platform’s output in FY2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY 2025 Value\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReflects accelerated pipeline advancement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased by $1.0 million due to cost discipline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBolstered by subsequent capital raises\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Assets Advanced\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e (IBIO-600, IBIO-610)\u003c\/td\u003e\n\u003ctd\u003eDirectly enabled by the platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Advantage\u003c\/h3\u003e\n\u003cp\u003eThe platform is the engine driving their entire pipeline strategy, making it a source of sustained competitive advantage. Because it is valuable, rare, and costly to imitate, and because iBio, Inc. is organized to exploit it - evidenced by the pipeline progress and capital structure - it provides a sustained advantage. This engine is what allows them to target difficult pathways in obesity, positioning them against competitors in a rapidly growing market projected to reach $612 billion by 2032. The platform's ability to engineer antibodies with extended half-life, like IBIO-600, is a key differentiator in a market where patient convenience matters immensely.\u003c\/p\u003e\n\u003cp\u003eVRIO Scoring Summary\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eAccelerates development; yields high-quality assets (e.g., IBIO-610)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique integration of Epitope steering, StableHu™, EngageTx™, ShieldTx®\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eProprietary datasets and fine-tuned algorithms are hard to replicate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eResources allocated (R\u0026amp;D spend of $8.3M) to advance platform-derived assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eThe core engine driving pipeline strategy and differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Proprietary Preclinical Pipeline Assets (Obesity\/Cardiometabolic Focus)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIBIO-610 (Activin E antibody) holds potential blockbuster candidacy, demonstrating a 26% reduction in fat mass in a 4-week study with obese mice while fully preserving muscle mass. When combined with a GLP-1 receptor agonist, this asset showed a synergistic effect, achieving a 77% reduction in total fat mass. IBIO-600 (anti-myostatin antibody) is in IND-enabling studies.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003ePreclinical Model\u003c\/th\u003e\n\u003cth\u003eKey Efficacy Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-610 (Activin E Ab)\u003c\/td\u003e\n\u003ctd\u003eObese Mice\u003c\/td\u003e\n\u003ctd\u003eFat Mass Reduction (Alone)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-610 (Activin E Ab) + GLP-1\u003c\/td\u003e\n\u003ctd\u003eObese Mice\u003c\/td\u003e\n\u003ctd\u003eTotal Fat Mass Reduction (Synergy)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-610 (Activin E Ab)\u003c\/td\u003e\n\u003ctd\u003eObese Mice\u003c\/td\u003e\n\u003ctd\u003eVisceral Fat Reduction (Alone)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34-37%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-610 (Activin E Ab)\u003c\/td\u003e\n\u003ctd\u003eObese NHPs\u003c\/td\u003e\n\u003ctd\u003ePredicted Human Half-Life\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e100 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 (Anti-Myostatin Ab)\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eDevelopment Stage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eIND-Enabling Studies\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The portfolio includes two distinct, in-licensed\/internally discovered assets, IBIO-600 and IBIO-610, both focused on obesity\/cardiometabolic disease and advanced into late preclinical stages.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Competitors can pursue similar targets, but iBio owns the specific intellectual property (IP) for these candidates, having in-licensed IBIO-600 and IBIO-610 from AstralBio, securing full development and commercialization rights.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGood. Financial commitment supports pipeline advancement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and Development (“R\u0026amp;D”) expenses for the fiscal year ended June 30, 2025, were $8.3 million.\u003c\/li\u003e\n\u003cli\u003eThis R\u0026amp;D expense represented an increase of approximately $3.1 million over fiscal year 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and restricted cash stood at $8.8 million as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company secured $6.2 million in gross proceeds through a warrant inducement transaction in April 2025 to support pipeline advancements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Advantage is contingent upon successful progression through clinical trials, as all assets are currently preclinical. IBIO-610's potential for infrequent dosing (predicted human half-life up to 100 days) offers a differentiated profile.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Strategic Collaboration and In-Licensing Agreements\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic Collaboration and In-Licensing Agreements\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eProvides access to de-risked assets like IBIO-600 and expands the discovery scope, as seen with the April 2025 amendment adding a fifth target with AstralBio. The collaboration structure led to the in-licensing of two advanced assets, IBIO-600 and IBIO-610, securing full development and commercialization rights. The initial multi-target discovery collaboration was entered into in April 2024, focusing on genetically validated pathways in obesity and cardiometabolic disease. The April 2025 amendment expanded this to a total of five targets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Agreement\u003c\/th\u003e\n\u003cth\u003eTarget\/Indication\u003c\/th\u003e\n\u003cth\u003eStatus\/Key Term\u003c\/th\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 (Myostatin License Agreement)\u003c\/td\u003e\n\u003ctd\u003eGDF8 (Myostatin) \/ Obesity\u003c\/td\u003e\n\u003ctd\u003eExclusive worldwide license, entered December 31, 2024\u003c\/td\u003e\n\u003ctd\u003ePotential milestones up to \u003cstrong\u003e$28 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-610 (Activin E Antibody)\u003c\/td\u003e\n\u003ctd\u003eActivin E \/ Obesity\u003c\/td\u003e\n\u003ctd\u003eExclusive license, entered April 21, 2025\u003c\/td\u003e\n\u003ctd\u003ePotential milestones up to \u003cstrong\u003e$28 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Amendment\u003c\/td\u003e\n\u003ctd\u003eFifth Target Added\u003c\/td\u003e\n\u003ctd\u003eApril 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$750,000\u003c\/strong\u003e credit provided by AstralBio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003ePartnerships are common, but securing in-licensing rights to assets identified using their own platform (like IBIO-600, identified by AstralBio using iBio's stack) is a unique monetization\/validation loop. The rapid advancement of IBIO-600 from inception to dosing in a non-human-primate study in just seven months is noted.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eHigh. Competitors would need to replicate the prior collaboration history and trust built with AstralBio, which began in April 2024.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eStrong. The collaboration structure is clearly defined and actively managed, leading to tangible pipeline additions. The company reported specific preclinical results supporting the assets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIBIO-610 demonstrated a \u003cstrong\u003e26% reduction in fat mass\u003c\/strong\u003e and no measurable loss of lean mass in a 4-week study in diet-induced obese mice.\u003c\/li\u003e\n\u003cli\u003eIBIO-600 demonstrated extended half-life in a non-GLP non-human primate (NHP) pharmacokinetics (PK) study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained. The established network and deal structure create a barrier. Financial metrics related to the period of these advancements include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenues for the fiscal year ended June 30, 2025, were approximately \u003cstrong\u003e$0.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for the fiscal year ended June 30, 2025, were \u003cstrong\u003e$8.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss for the fiscal year ended June 30, 2025, was approximately \u003cstrong\u003e$18.4 million\u003c\/strong\u003e, or \u003cstrong\u003e$1.75 per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and restricted cash totaled \u003cstrong\u003e$8.8 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Integrated Contract Development and Manufacturing (CDMO) Services\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Generates revenue (FY2025 revenue was \u003cstrong\u003e$0.4 million\u003c\/strong\u003e) and historically ensured seamless scale-up for their own pipeline, minimizing variability from bench to launch. The CDMO segment previously accounted for \u003cstrong\u003e53.71%\u003c\/strong\u003e of total revenue in FY2021, with $\u003cstrong\u003e1.27 million\u003c\/strong\u003e generated in that period.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs offer CDMO services, but iBio’s integrated model, where the same team handled development and manufacturing, was less common prior to the divestiture.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Required significant capital investment in facilities and regulatory compliance, which was a hurdle for smaller players. The acquisition of the Bryan, Texas facility and subsidiary involved an investment of approximately \u003cstrong\u003e$6 million\u003c\/strong\u003e in cash and debt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Transitioned. The segment was a distinct operational segment supporting the core business, which included a \u003cstrong\u003e130,000 square-foot\u003c\/strong\u003e cGMP manufacturing facility. The Company completed its transition from a CDMO to an AI-driven biologics company following the sale of this facility in June 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It was a necessary service capability, not a primary differentiator unless executed at massive scale, and the capability has since been largely divested.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Financial and Operational Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY2025 Total Revenue: \u003cstrong\u003e$0.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHistorical CDMO Revenue Contribution (FY2021): \u003cstrong\u003e$1.27 million\u003c\/strong\u003e, representing \u003cstrong\u003e53.71%\u003c\/strong\u003e of total revenue.\u003c\/li\u003e\n\u003cli\u003eHistorical CDMO Facility Acquisition Investment (Nov 2021): Approximately \u003cstrong\u003e$6 million\u003c\/strong\u003e in cash and debt.\u003c\/li\u003e\n\u003cli\u003eHistorical Secured Debt Associated with Facility: \u003cstrong\u003e$22,375,000\u003c\/strong\u003e term loan.\u003c\/li\u003e\n\u003cli\u003eBryan, Texas Facility Sale Price (June 2024): \u003cstrong\u003e$8.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSecured Debt Eliminated from Sale: Approximately \u003cstrong\u003e$13.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Equivalents (June 30, 2025): \u003cstrong\u003e$8.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eHistorical CDMO Segment Financial Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.27 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended June 30, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Revenue Percentage of Total\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53.71%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended June 30, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Quarterly Revenue Percentage (Mar 2022)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.36%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended March 31, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Acquisition Investment\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNovember 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Sale Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Balance Sheet Strength from Capital Events\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProvided working capital to fund the $8.3 million in R\u0026amp;D expenses in FY2025 and supported operations while G\u0026amp;A was $10.7 million.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expenses for the fiscal year ended June 30, 2025: $8.3 million.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative Expenses for the fiscal year ended June 30, 2025: approximately $10.7 million.\u003c\/li\u003e\n\u003cli\u003eCash and equivalents as of June 30, 2025: $8.6 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow. Capital raising is standard for biotech, but the successful execution of a $46.5 million public offering and a $6.2 million warrant inducement in FY2025 is notable.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCapital Event (FY2025)\u003c\/th\u003e\n\u003cth\u003eGross Proceeds (Approx.)\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eKey Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$46.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003ctd\u003eUnderwritten offering of pre-funded warrants and warrants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrant Inducement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApril 2025\u003c\/td\u003e\n\u003ctd\u003eExercise of warrants for 5,626,685 shares at $1.11 per share; issuance of new warrants at $0.86.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Private Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$655,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025\u003c\/td\u003e\n\u003ctd\u003eProceeds intended for working capital purposes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATM Agreement Sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$102,000\u003c\/strong\u003e (Net)\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025\u003c\/td\u003e\n\u003ctd\u003eNet proceeds from shares sold under At Market Issuance Sales Agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow. Any company can raise capital if the market allows.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nStrong. Management executed multiple funding events effectively to secure runway.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nNone. This is a necessary condition for survival, not a source of advantage.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Engineering for Extended Half-Life and Reduced Dosing\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nDirectly addresses a major patient pain point with current obesity drugs - frequent injections - by designing candidates like IBIO-600 for subcutaneous, extended-release administration.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nIBIO-600 human half-life estimated range: \u003cstrong\u003e57-130 days\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nPotential dosing schedule: once every \u003cstrong\u003e3 to 6-month\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. While a goal for many, iBio’s platform is explicitly geared toward achieving this design parameter.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. It requires specific molecular engineering expertise embedded in their platform technology.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nIBIO-600 engineered to bind to the FcRn receptor with \u003cstrong\u003emore than 10-fold higher affinity\u003c\/strong\u003e than normal IgG.\n\u003c\/li\u003e\n\u003cli\u003e\nPlatform components include patented AI-driven Epitope Engineering Engine and StableHu™ Antibody Optimizer.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nStrong. This design principle is a core tenet of their current pipeline development.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Asset\/Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 Regulatory Submission Target\u003c\/td\u003e\n\u003ctd\u003eTarget Quarter\/Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 NHP Half-Life\u003c\/td\u003e\n\u003ctd\u003eStandard PK Calculation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40 to 52 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 Lean Mass Increase (High-Dose NHP)\u003c\/td\u003e\n\u003ctd\u003ePeak Effect (8 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.1% (270g)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 Upfront In-License Payment\u003c\/td\u003e\n\u003ctd\u003eAmount Paid to AstralBio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$750,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIBIO-600 Potential Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eTotal Potential\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$28 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSustained. If successful in clinic, this feature will be a major differentiator against established therapies.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nFiscal Year 2025 (ended June 30, 2025) R\u0026amp;D Expenses: \u003cstrong\u003e$8.3 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nCash, cash equivalents, and restricted cash as of September 30, 2024: approximately \u003cstrong\u003e$11.3 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nFiscal Year 2025 Revenue: approximately \u003cstrong\u003e$0.4 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Nasdaq Stock Market Listing\n\u003c\/h2\u003e\n\u003cp\u003eThe transfer of listing to the Nasdaq Capital Market, effective on \u003cstrong\u003eMarch 4, 2025\u003c\/strong\u003e, from the NYSE American, represents a significant administrative and structural event for iBio, Inc..\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eEnhanced corporate visibility, improved trading liquidity, and alignment with a strategy to attract long-term institutional investors.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow. It’s a corporate milestone, not a core operational asset.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow. It is an administrative\/regulatory achievement.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eGood. The move was executed and is now a stable part of their corporate structure.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone. It's a prerequisite for broader institutional access.\u003c\/p\u003e\n\n\u003cp\u003eThe operational context surrounding the listing includes the following financial statistics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Exchange Listing\u003c\/td\u003e\n\u003ctd\u003eNasdaq Capital Market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTicker Symbol\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eIBIO\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.49m\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Example)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$49.92M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (FY 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$400.00K\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (FY 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$18.38M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Price Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.5562\u003c\/strong\u003e to \u003cstrong\u003e$6.89\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe VRIO assessment components are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eEnhanced corporate visibility, improved trading liquidity, and alignment with a strategy to attract long-term institutional investors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLow. It’s a corporate milestone, not a core operational asset.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow. It is an administrative\/regulatory achievement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eGood. The move was executed and is now a stable part of their corporate structure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eNone. It's a prerequisite for broader institutional access.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther details relevant to the corporate structure and market access include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's common stock was approved for listing on the Nasdaq Capital Market on February 19, 2025.\u003c\/li\u003e\n\u003cli\u003eConsolidated market data for IBIO on Nasdaq is disseminated via the UTP Quotation Data Feed (UQDF) and UTP Trade Data Feed (UTDF) beginning in pre-market trading hours on March 4, 2025.\u003c\/li\u003e\n\u003cli\u003eThe CUSIP for iBio Inc. is \u003cstrong\u003e451033708\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Nasdaq Market Category for the listing is \u003cstrong\u003eNasdaq Capital Market\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Proprietary 3D Modeling and Computational Biology\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eProprietary 3D Modeling and Computational Biology\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Metric\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eFoundation for AI engine\u003c\/td\u003e\n\u003ctd\u003eEnables predicted human half-life up to \u003cstrong\u003e100 days\u003c\/strong\u003e for IBIO-610.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSpecific integration of 3D modeling with antibody platforms is proprietary.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eRelies on years of accumulated data and specialized software development (e.g., StableHu technology).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eBase layer supporting pipeline assets with potential contingent payments up to \u003cstrong\u003e$52.5MM\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eCore, non-codified knowledge asset underpinning drug discovery.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe platform's output directly influences financial milestones and pipeline advancement.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nIBIO-610 (Activin E Antibody) predicted human half-life: up to \u003cstrong\u003e100 days\u003c\/strong\u003e, suggesting dosing as infrequently as \u003cstrong\u003etwice per year\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nIBIO-600 (Anti-Myostatin Antibody) projected human half-life: up to \u003cstrong\u003e130 days\u003c\/strong\u003e, potentially enabling dosing \u003cstrong\u003eonce every three to six months\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nUpfront cash from an early-stage asset sale driven by the platform: \u003cstrong\u003e$1MM\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nTotal Research \u0026amp; Development Expenses (Last 12 Months): \u003cstrong\u003e$6,228.0K\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nCash, cash equivalents and restricted cash as of June 30, 2024: \u003cstrong\u003e$14.4 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nFull-time employees: \u003cstrong\u003e20\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe technology facilitates the discovery of candidates like IBIO-610, which demonstrated an extended half-life of \u003cstrong\u003e33.2 days\u003c\/strong\u003e in obese non-human primates.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eiBio, Inc. (IBIO) - VRIO Analysis: Experienced Leadership and Governance Additions\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eExperienced Leadership and Governance Additions Assessment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides expert guidance in protein sciences, microbiology, and regulatory affairs, fortifying credibility for investors and partners.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Experienced leaders are sought after, but the recent additions signal a clear strategic direction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Key individuals can leave, but the structure of an experienced board is imitable over time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. The new team is positioned to execute the growth strategy moving into FY2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Relies on the tenure and continued presence of specific individuals.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eRole\/Addition\u003c\/td\u003e\n\u003ctd\u003eName(s)\u003c\/td\u003e\n\u003ctd\u003eRelevant Experience\/Focus Area\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Director Addition (Nov 2024)\u003c\/td\u003e\n\u003ctd\u003eDavid Arkowitz\u003c\/td\u003e\n\u003ctd\u003eFinance, Operations; CFO at Seres Therapeutics, Flexion Therapeutics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Director Addition (Nov 2024)\u003c\/td\u003e\n\u003ctd\u003eAntónio Parada\u003c\/td\u003e\n\u003ctd\u003eAntibody Discovery; Founder\/CEO of FairJourney Biologics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO \u0026amp; CSO\u003c\/td\u003e\n\u003ctd\u003eMartin Brenner, Ph.D., DVM\u003c\/td\u003e\n\u003ctd\u003eDrug Discovery \u0026amp; Development (AstraZeneca, Pfizer, Merck Research Labs)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFO\u003c\/td\u003e\n\u003ctd\u003eFelipe Duran\u003c\/td\u003e\n\u003ctd\u003eFinancial Planning \u0026amp; Analysis; Lupin Latin America CFO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe strategic pipeline focus includes IBIO-610, with expected human trials in early 2027.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLatest Relevant Financial Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of Q3 2025 end (September 30, 2025): \u003cstrong\u003e$\\text{\\$28.1}$ million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Cash (Most Recent Quarter Reported): \u003cstrong\u003e$\\text{\\$49.57}$ million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Debt (Most Recent Quarter Reported): \u003cstrong\u003e$\\text{\\$3.29}$ million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiscal Year 2025 Operating Activities Cash Flow: \u003cstrong\u003e$-\\text{\\$12.2}$ million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrailing Twelve Months Net Income (TTM): \u003cstrong\u003e$-\\text{\\$20.11}$ million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003e13-Week Cash Flow Projection Incorporating $\\text{\\$46.5}$ Million Offering Proceeds (Draft)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis projection assumes the $\\text{\\$46.5}$ million net proceeds from the offering are received in Week 1.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{\\$28.1}$ million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(Calculated End Cash W1)\u003c\/td\u003e\n\u003ctd\u003e(Calculated End Cash W2)\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e(Calculated End Cash W12)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Inflow (Offering Proceeds)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{\\$46.5}$ million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$\\text{0}$\u003c\/td\u003e\n\u003ctd\u003e$\\text{0}$\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e$\\text{0}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Outflow (Operating\/Investing)\u003c\/td\u003e\n\u003ctd\u003e(Estimated Weekly Spend)\u003c\/td\u003e\n\u003ctd\u003e(Estimated Weekly Spend)\u003c\/td\u003e\n\u003ctd\u003e(Estimated Weekly Spend)\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e(Estimated Weekly Spend)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003e(Calculated Value)\u003c\/td\u003e\n\u003ctd\u003e(Calculated Value)\u003c\/td\u003e\n\u003ctd\u003e(Calculated Value)\u003c\/td\u003e\n\u003ctd\u003e...\u003c\/td\u003e\n\u003ctd\u003e(Calculated Value)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516184256661,"sku":"ibio-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ibio-vrio-analysis.png?v=1740183177","url":"https:\/\/dcf-model.com\/pt\/products\/ibio-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}